Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 9/20 | 0.54 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.54 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.54 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.54 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.54 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.54 |
| ▸ | GPR183 | P32249 | 1/20 | 0.54 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8498934 | 1.00 | S1PR1 (0.54) | S1PR1TNNC1S1PR3S1PR4S1PR5 | |
| SCHEMBL8496582 | 1.00 | S1PR1 (0.54) | S1PR1TNNC1S1PR3S1PR4S1PR5 | |
| SCHEMBL8498784 | 0.98 | S1PR1 (0.53) | S1PR1TNNC1S1PR3S1PR4S1PR5 | |
| SCHEMBL8498104 | 0.96 | S1PR1 (0.60) | S1PR1TNNC1S1PR3S1PR4S1PR5 | |
| SCHEMBL8496393 | 0.96 | S1PR1 (0.60) | S1PR1TNNC1S1PR3S1PR4S1PR5 | |
| SCHEMBL8498823 | 0.96 | S1PR1 (0.60) | S1PR1TNNC1S1PR3S1PR4S1PR5 | |
| SCHEMBL6036013 | 0.95 | S1PR1 (0.53) | S1PR1TNNC1S1PR3S1PR4S1PR5 | |
| SCHEMBL8496107 | 0.94 | S1PR1 (0.58) | S1PR1TNNC1S1PR3S1PR4S1PR5 | |
| SCHEMBL8497910 | 0.94 | S1PR1 (0.58) | S1PR1TNNC1S1PR3S1PR4S1PR5 | |
| SCHEMBL8499382 | 0.94 | S1PR1 (0.58) | S1PR1TNNC1S1PR3S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0627406-B1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL (JP) | 1998-10-28 | — | — | EP | claimed |
| EP-0627406-A1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-12-07 | — | — | EP | claimed |
| US-9763980-B2 | Combined chemical modification of sphingosine-1-phosphate (S1P) and CXCR4 signalling pathways for hematopoietic stem cell (HSC) mobilization and engraftment | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-09-19 | — | — | US | disclosed |
| US-20140193376-A1 | COMBINED CHEMICAL MODIFICATION OF SPHINGOSINE-1-PHOSPHATE (S1P) AND CXCR4 SIGNALLING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND ENGRAFTMENT | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-07-10 | — | — | US | disclosed |
| EP-2720690-A1 | COMBINED CHEMICAL MODIFICATION OF SPHINGOSINE-1-PHOSPHATE (S1P) AND CXCR4 SIGNALLING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND ENGRAFTMENT | Children's Medical Center Corporation (US) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012174522-A1 | COMBINED CHEMICAL MODIFICATION OF SPHINGOSINE-1-PHOSPHATE (S1P) AND CXCR4 SIGNALLING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND ENGRAFTMENT | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2012-12-20 | — | — | WO | disclosed |
| US-5952316-A | FOR TREATING AUTOIMMUNE DISEASES, E.G., RHEUMATIOD ARTHRITIS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-09-14 | — | — | US | disclosed |
| EP-0627406-B1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL (JP) | 1998-10-28 | — | — | EP | disclosed |
| US-5719176-A | 2-amino-1,3-propanediol compound and immunosuppressant | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-02-17 | — | — | US | disclosed |
| US-5604229-A | 2-amino-1,3-propanediol compound and immunosuppressant | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-02-18 | — | — | US | disclosed |
| EP-0627406-A1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140193376-A1 | COMBINED CHEMICAL MODIFICATION OF SPHINGOSINE-1-PHOSPHATE (S1P) AND CXCR4 SIGNALLING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND ENGRAFTMENT | S1PR1, S1PR4, S1PR3 | S1PR1 1/4885TNNC1 4794/4885S1PR3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.